WeylChem InnoTec specializes in advanced chemical and pharmaceutical services, focusing on analytics, contract research, and custom synthesis. The company offers a suite of services including analytical services, quality control, process development, and specialized custom synthesis for the fine chemical and pharmaceutical industry. WeylChem InnoTec serves various sectors within read morethe fine chemical and pharmaceutical industries, providing innovative solutions for complex chemical processes. It is based in Frankfurt, Germany. [website]

Wilmington PharmaTech is a full service CRO serving pharmaceutical and biotechnology companies in five major areas including 1) cGMP synthesis, 2) Salt and Polymorph Studies (to discover a suitable salt and crystal form), 3) FTE Research (process or medicinal chemistry performed either in the US or China), 4) Analytical Services (e.g. read moremethod development, method validation, trace analysis), and 5) Bulk Intermediate Synthesis (kgs to tons). Wilmington PharmaTech currently has two locations in Newark, Delaware (Delaware Technology Park and Pencader Corporate Center) with process research labs, solid state chemistry lab, analytical lab, and cGMP kilo labs. The company is also expanding its non-GMP bulk intermediate production in China. [website]

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi read moreAppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its openaccess platform is enabling more than 5,800 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com